United States Biotechnology & Medical Research

Chemomab Therapeutics Ltd (CMMB)

Track

Chemomab Therapeutics Ltd has seen no insider trading activity in the last 90 days. The most recent transaction occurred on September 12, 2024, involving a proposed sale of 500,000 shares by OrbiMed Israel Partners Limited Partnership. Prior to this, historical activity consisted primarily of sales by major shareholders and executives.
Ticker: CMMB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Chemomab Therapeutics Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
OrbiMed Israel Partners Limited Partnership
Owner
1 sale — total 1,015,000 USD
Proposed sale 12 Sep 2024
Value US$796,560.88 | Price 185.83 | Shares 88,377
Planned sale 3 Jan 2023
Value US$911,301.94 | Price 499.06 | Shares 68,670
Planned sale 3 Jan 2023
Value US$3,691,178.72 | Price 254.79 | Shares 85,419
Sale 3 Jan 2023
Value US$318,063.24 | Price 4.51 | Shares 70,524
Sale 3 Jan 2023
Value US$889,695.84 | Price 3.34 | Shares 266,376
Sale 16 Nov 2022
Value US$4,818.00 | Price 2.00 | Shares 2,409
Sale 16 Nov 2022
Value US$536,310.63 | Price 2.08 | Shares 257,248
Sale 16 Nov 2022
Value US$677,090.92 | Price 2.08 | Shares 324,775
Buy 24 May 2022
Value US$91.08 | Price 2.76 | Shares 33
Buy 24 May 2022
Value US$1,156.00 | Price 2.89 | Shares 400
Buy 18 May 2022
Value US$6,380.00 | Price 3.19 | Shares 2,000
Buy 18 Mar 2022
Value US$2,180.00 | Price 4.36 | Shares 500
Buy 18 Mar 2022
Value US$2,160.00 | Price 4.32 | Shares 500
Buy 16 Mar 2022
Value US$812.50 | Price 3.25 | Shares 250
Buy 16 Mar 2022
Value US$825.00 | Price 3.30 | Shares 250
Buy 14 Mar 2022
Value US$1,050.00 | Price 4.20 | Shares 250
Buy 14 Mar 2022
Value US$1,025.00 | Price 4.10 | Shares 250
Buy 14 Mar 2022
Value US$975.00 | Price 3.90 | Shares 250
Buy 14 Mar 2022
Value US$995.00 | Price 3.98 | Shares 250
Buy 14 Mar 2022
Value US$1,000.00 | Price 4.00 | Shares 250
Buy 14 Mar 2022
Value US$2,779.00 | Price 3.97 | Shares 700
Buy 14 Mar 2022
Value US$7,164.00 | Price 3.98 | Shares 1,800
Buy 14 Mar 2022
Value US$9,120.00 | Price 4.56 | Shares 2,000
Buy 14 Mar 2022
Value US$8,600.00 | Price 4.30 | Shares 2,000
Buy 14 Mar 2022
Value US$8,400.00 | Price 4.20 | Shares 2,000
Buy 11 Mar 2022
Value US$5,136.00 | Price 4.28 | Shares 1,200
Buy 6 Dec 2021
Value US$14,860.00 | Price 7.43 | Shares 2,000
Buy 16 Mar 2021
Value US$99,997.59 | Price 41.51 | Shares 2,409
Buy 16 Mar 2021
Value US$0.00 | Price 0.00 | Shares 230,536
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-12 2024-09-12 PrS Proposed sale
3.9
OrbiMed Israel Partners Limited Partnership

Owner
88,377
185.83
US$796,561 		88,377 185.83 US$796,561
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
68,670 +4.4%
499.06
US$911,302 		68,670 +4.4% 499.06 US$911,302
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
85,419 -20.5%
254.79
US$3,691,179 		85,419 -20.5% 254.79 US$3,691,179
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
70,524 -3.1%
4.51
US$318,063 		70,524 -3.1% 4.51 US$318,063
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
266,376 -10.3%
3.34
US$889,696 		266,376 -10.3% 3.34 US$889,696
2022-11-18 2022-11-16 S Sale
1.3
Cohen Neil Harris
Non-Executive Director
2,409 -19.4%
2.00
US$4,818 		2,409 -19.4% 2.00 US$4,818
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
257,248 -50.0%
2.08
US$536,311 		257,248 -50.0% 2.08 US$536,311
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
324,775 -50.0%
2.08
US$677,091 		324,775 -50.0% 2.08 US$677,091
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
33 +2.4%
2.76
US$91 		33 +2.4% 2.76 US$91
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
400 +40.0%
2.89
US$1,156 		400 +40.0% 2.89 US$1,156
2022-05-19 2022-05-18 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,000 +19.2%
3.19
US$6,380 		2,000 +19.2% 3.19 US$6,380
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +100.0%
4.36
US$2,180 		500 +100.0% 4.36 US$2,180
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +inf%
4.32
US$2,160 		500 +inf% 4.32 US$2,160
2022-06-21 2022-03-16 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +14.3%
3.25
US$812 		250 +14.3% 3.25 US$812
2022-06-21 2022-03-16 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +16.7%
3.30
US$825 		250 +16.7% 3.30 US$825
2022-03-21 2022-03-14 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +20.0%
4.20
US$1,050 		250 +20.0% 4.20 US$1,050
2022-03-21 2022-03-14 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +25.0%
4.10
US$1,025 		250 +25.0% 4.10 US$1,025
2022-03-21 2022-03-14 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +33.3%
3.90
US$975 		250 +33.3% 3.90 US$975
2022-03-21 2022-03-14 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +100.0%
3.98
US$995 		250 +100.0% 3.98 US$995
2022-03-21 2022-03-14 B Purchase
1.5
Marvin Donald

Executive VP, CFO & COO

Officer
250 +inf%
4.00
US$1,000 		250 +inf% 4.00 US$1,000
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
700 +38.9%
3.97
US$2,779 		700 +38.9% 3.97 US$2,779
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
1,800 +inf%
3.98
US$7,164 		1,800 +inf% 3.98 US$7,164
2022-03-15 2022-03-14 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,000 +23.8%
4.56
US$9,120 		2,000 +23.8% 4.56 US$9,120
2022-03-15 2022-03-14 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,000 +31.2%
4.30
US$8,600 		2,000 +31.2% 4.30 US$8,600
2022-03-15 2022-03-14 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,000 +45.4%
4.20
US$8,400 		2,000 +45.4% 4.20 US$8,400
2022-03-14 2022-03-11 B Purchase
0.9
Darvish Nissim
Non-Executive Director
1,200 +inf%
4.28
US$5,136 		1,200 +inf% 4.28 US$5,136
2021-12-08 2021-12-06 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,000 +83.0%
7.43
US$14,860 		2,000 +83.0% 7.43 US$14,860
2021-03-26 2021-03-16 B Purchase
1.3
Cohen Neil Harris
Non-Executive Director
2,409 +inf%
41.51
US$99,998 		2,409 +inf% 41.51 US$99,998
2021-03-18 2021-03-16 B Purchase
1.3
THIEL PETER
Large shareholder
230,536
0.00
US$0 		230,536 0.00 US$0
Explore more

More insider trading research around Chemomab Therapeutics Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America